Ondansetron B. Braun

Ondansetron, the active ingredient in Ondansetron B. Braun, is a 5‑HT3 receptor antagonist presented as an intravenous solution for intravenous use. It is employed to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, and postoperative conditions in adult patients.

GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, with distribution aligned to EU market standards. The company ensures quality and regulatory compliance throughout the supply chain through rigorous testing and documentation.

Ondansetron acts on the serotonergic pathway to control emesis in several clinical settings.

Chemotherapy-induced nausea and vomiting: reduces incidence and severity of acute and delayed episodes. Radiotherapy-induced nausea and vomiting: prevents onset of nausea during and after treatment. Postoperative nausea and vomiting: minimizes postoperative symptoms and improves patient comfort.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Dizziness: transient sensation of lightheadedness. - Fatigue: general feeling of tiredness. - Diarrhea: loose stools in some patients. - Injection site reactions: redness or discomfort at the IV site.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe allergic reactions: anaphylaxis or angioedema. - Serotonin syndrome: risk when combined with other serotonergic agents. - Hypotension: sudden drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Hepatic dysfunction: abnormal liver enzyme elevations.

Precautions should be observed when using Ondansetron B. Braun.

Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. Hepatic impairment: consider dose modification for patients with liver disease. Electrolyte disturbances: correct potassium or magnesium abnormalities before administration. Concomitant QT‑prolonging drugs: use with caution to avoid additive cardiac effects. Pregnancy: risk unknown; prescribe only if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medications.

Major Interactions (Avoid): - Other QT‑prolonging agents: increase risk of arrhythmia. - Apomorphine: may cause severe hypotension. - Serotonergic drugs (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase ondansetron levels. - CYP3A4 inducers (e.g., rifampin): may reduce ondansetron efficacy. - Aminoglycoside antibiotics: may enhance QT prolongation risk.